Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Minerva Surgical, Inc. (UTRS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Healthcare Information Services
Address
4255 Burton Drive 95054
Santa Clara, CA, US
Santa Clara, CA, US
CEO
Darin Hammers
Website
minervasurgical.com
IPO
2021-10-22
CIK 1452965 ISIN US60343F2056
Description
Minerva Surgical, Inc. functions as a commercial-stage medical technology enterprise, specializing in the creation, production, and distribution of innovative, minimally invasive solutions tailored to address the uterine healthcare needs of women throughout the United States. Their suite of offerings features advanced endometrial ablation systems, including the Minerva ES and Genesys HTA. They also provide the Symphion Tissue Removal System, a sophisticated, minimally invasive device for uterine tissue removal that uniquely integrates bladeless tissue resection, coagulation capabilities, continuous visualization during procedures, and precise intrauterine pressure monitoring. Additionally, the Resectr Tissue Resection Device is a handheld surgical tool engineered for the hysteroscopic removal and diagnostic evaluation of endometrial polyps. These specialized instruments are utilized by obstetrician-gynecologists across a variety of clinical settings, such as hospitals, outpatient ambulatory surgical centers, and private physician practices. The company was founded in 2008 and is headquartered in Santa Clara, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
33
Beta
4.60
Float Shares
961.3K
Free Float %
10.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +9,900.00% | +0.00% | +0.00% | -90.00% | +0.00% | +0.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Low
100.00
+99,999,900.0%
Consensus
100.00
+99,999,900.0%
Median
100.00
+99,999,900.0%
High
100.00
+99,999,900.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
100.00
+99,999,900.0%
|
Quality scores
Altman Z-Score
-6.27
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%-3.5% Q3'23: -4.9% (vs Q3'22)
-
EPS growth Medical - Healthcare Information Services: +43.1%-58.1% Q3'23: +89.8% (vs Q3'22)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-68.5% Q3'23: -42.7% (vs Q3'22)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-61.4% Q3'23: -50.2% (vs Q3'22)
-
ROIC Medical - Healthcare Information Services: +5.2%-61.9% Q3'23: -45.6% (vs Q3'22)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.6% Q3'23: +520.5% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-1.98× Q3'23: -2.39× (vs Q3'22)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|
| Revenue |
52.10M
est: 51.71M (+0.8%)
|
50.29M
est: 51.00M (-1.4%)
|
51.81M
est.
|
59.61M
est.
|
68.53M
est.
|
| EBITDA |
893.0K
est: -13.43M (+106.6%)
|
-20.07M
est: -13.25M (-51.5%)
|
-13.46M
est.
|
-15.48M
est.
|
-17.80M
est.
|
| EBIT |
-9.73M
est: -22.25M (+56.3%)
|
-30.88M
est: -21.95M (-40.7%)
|
-22.30M
est.
|
-25.65M
est.
|
-29.49M
est.
|
| Net Income |
-21.46M
est: -97.16M (+77.9%)
|
-34.11M
est: -36.30M (+6.0%)
|
-5.86M
est.
|
-4.16M
est.
|
-4.03M
est.
|
| SGA |
54.38M
est: 52.87M (+2.8%)
|
52.70M
est: 52.15M (+1.1%)
|
52.98M
est.
|
60.95M
est.
|
70.07M
est.
|
| EPS |
-14.98
est: -67.45 (+77.8%)
|
-23.68
est: -25.20 (+6.0%)
|
-4.07
est.
|
-2.89
est.
|
-2.80
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-38.66M
OE per share TTM
-8.41
Owner's Yield
-4,357,137.30%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Accelmed Partners II GP L.P. | 122.19M | 69.30% | 122.19M | — | 122.19M | — | PN | — | 2023-02-09 | ↗ |
| 2 | Accelmed Partners II L.P. | 122.19M | 69.30% | 122.19M | — | 122.19M | — | PN | — | 2023-02-09 | ↗ |
| 3 | Uri Geiger | 122.19M | 69.30% | 122.19M | — | 122.19M | — | IN | — | 2023-02-09 | ↗ |
| 4 | Baskett | 10.00M | 35.00% | — | 10.00M | — | 10.00M | IN | States | 2021-11-17 | ↗ |
| 5 | Enterprise Associates 13, L.P. | 10.00M | 35.00% | — | 10.00M | — | 10.00M | PN | Cayman Islands | 2021-11-17 | ↗ |
| 6 | NEA 13 GP, LTD | 10.00M | 35.00% | — | 10.00M | — | 10.00M | CO | Cayman Islands | 2021-11-17 | ↗ |
| 7 | Partners 13, L.P. | 10.00M | 35.00% | — | 10.00M | — | 10.00M | PN | Cayman Islands | 2021-11-17 | ↗ |
| 8 | Patrick J. Kerins | 10.00M | 35.00% | — | 10.00M | — | 10.00M | IN | States | 2021-11-17 | ↗ |
| 9 | Scott D. Sandell | 10.00M | 35.00% | — | 10.00M | — | 10.00M | IN | States | 2021-11-17 | ↗ |
| 10 | CVF, LLC | 2.26M | 7.80% | 2.26M | — | 2.26M | — | OO | Delaware | 2022-02-10 | ↗ |
| 11 | Vivo Ventures VII, LLC | 2.22M | 7.80% | 2.22M | — | 2.22M | — | OO | Delaware | 2021-11-01 | ↗ |
| 12 | Novo Holdings A/S | 2.06M | 7.20% | 2.06M | — | 2.06M | — | CO | Denmark | 2021-10-27 | ↗ |
| 13 | Versant Ventures IV, LLC | 1.67M | 5.80% | — | 1.67M | — | 1.67M | OO | — | 2022-02-11 | ↗ |
| 14 | Versant Venture Capital IV, L.P. | 1.66M | 5.80% | 1.66M | — | 1.66M | — | PN | — | 2022-02-11 | ↗ |
| 15 | Versant Side Fund IV, L.P. | 10.5K | 0.00% | 10.5K | — | 10.5K | — | PN | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Buys
1
Sells
1
Shares acquired
24.44M
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+24,437,927
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | Cohen Daniel | Director | — | I | Common Stock | 0 | 0.00 | — | 122,189,638 | — | ↗ |
| 2023-02-09 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | P-Purchase | A | Common Stock | 24,437,927 | 0.20 | 5.00M | 34,437,052 | — | ↗ |
| 2023-02-09 | Geiger Uri | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 122,189,638 | — | ↗ |
| 2023-02-09 | Accelmed Partners II L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 122,189,638 | — | ↗ |
| 2023-01-02 | Usen Todd | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-19 | Sung Derrick | Director | A-Award | A | Common Stock | 86,956 | 2.30 | 200.0K | 86,956 | — | ↗ |
| 2022-06-10 | Renzi David | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 49,792 | — | ↗ |
| 2022-06-10 | JAFFE ROSS A MD | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 49,792 | — | ↗ |
| 2022-06-10 | Hunt Niquette L. | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 49,792 | — | ↗ |
| 2022-06-10 | Coste Catherine | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 129,579 | — | ↗ |
| 2022-06-10 | Behbahani Ali | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 58,279 | — | ↗ |
| 2022-06-10 | Anderson Jill | Director | A-Award | A | Common Stock | 49,792 | 2.41 | 120.0K | 49,792 | — | ↗ |
| 2022-05-02 | Skalnyi Evgueni V. | Officer | A-Award | A | Common Stock | 49,755 | 0.00 | — | 244,725 | — | ↗ |
| 2022-05-02 | Jung Joel R | Officer | A-Award | A | Common Stock | 60,198 | 0.00 | — | 220,730 | — | ↗ |
| 2022-05-02 | Filloux Dominique J. | Officer | A-Award | A | Common Stock | 60,198 | 0.00 | — | 266,289 | — | ↗ |
| 2022-05-02 | Clapper David M | Officer | A-Award | A | Common Stock | 229,732 | 0.00 | — | 323,232 | — | ↗ |
| 2021-12-15 | Skalnyi Evgueni V. | Officer | A-Award | A | Common Stock | 20,250 | 0.00 | — | 194,970 | — | ↗ |
| 2021-12-15 | Jung Joel R | Officer | A-Award | A | Common Stock | 24,500 | 0.00 | — | 160,532 | — | ↗ |
| 2021-12-15 | Filloux Dominique J. | Officer | A-Award | A | Common Stock | 24,500 | 0.00 | — | 206,091 | — | ↗ |
| 2021-12-15 | Clapper David M | Director / Officer | A-Award | A | Common Stock | 93,500 | 0.00 | — | 93,500 | — | ↗ |
| 2021-12-13 | Clapper David M | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 4.94 | 123.4K | 642,660 | — | ↗ |
| 2021-10-26 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 580,000 | 12.00 | 6.96M | 2,057,132 | — | ↗ |
| 2021-10-26 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | C-Conversion | D | Series D Preferred Stock | 3,503,021 | 0.00 | — | 0 | — | ↗ |
| 2021-10-26 | JAFFE ROSS A MD | Director | C-Conversion | A | Common Stock | 284,437 | 0.00 | — | 284,437 | I | ↗ |
| 2021-10-26 | Behbahani Ali | Director | C-Conversion | A | Series D Preferred Stock | 742 | 0.00 | — | 3,306 | — | ↗ |
| 2021-10-21 | Skalnyi Evgueni V. | Officer | — | D | Stock Option (Right to Buy) | 71,782 | 13.12 | 941.8K | 0 | — | ↗ |
| 2021-10-21 | Renzi David | Director | — | D | Stock Option (Right to Buy) | 18,010 | 13.12 | 236.3K | 0 | — | ↗ |
| 2021-10-21 | Novo Holdings A/S | 10% Owner | — | D | SERIES D REDEEMABLE CONVERTIBLE PREFERRED STOCK | 884,484 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | — | D | Series C Preferred Stock | 1,190,212 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | JAFFE ROSS A MD | Director | — | I | Subordinated Secured Convertible Promissory Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Hunt Niquette L. | Director | — | D | Stock Option (Right to Buy) | 60,783 | 13.12 | 797.5K | 0 | — | ↗ |
| 2021-10-21 | Filloux Dominique J. | Officer | — | D | Common Stock | 0 | 0.00 | — | 181,591 | — | ↗ |
| 2021-10-21 | Clapper David M | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 617,660 | — | ↗ |
| 2021-10-21 | Behbahani Ali | Director | — | D | Series C Preferred Stock | 704 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | Anderson Jill | Director | — | D | Stock Option (Right to Buy) | 60,783 | 13.12 | 797.5K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-177.5K
Shares Outstanding
8.88M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Joel R. Jung Chief Financial Officer | 565.6K | — | 604.2K | — | — | — | 1.17M | 51.65% | ↗ |
| 2 | 2022 | Dominique J. Filloux Chief Operating Officer | 400.6K | — | 158.3K | — | — | — | 558.9K | 28.33% | ↗ |
| 3 | 2021 | David M. Clapper Former President and Chief Executive Officer | 509.8K | 338.9K | 483.4K | 3.09M | — | 229.00 | 4.42M | 80.81% | ↗ |
| 4 | 2021 | Joel R. Jung Chief Financial Officer | 509.8K | 338.9K | 483.4K | 3.09M | — | 229.00 | 4.42M | 80.81% | ↗ |
| 5 | 2021 | Dominique J. Filloux Chief Operating Officer | 347.8K | 123.5K | 126.7K | 1.20M | — | 351.00 | 1.80M | 73.81% | ↗ |
| 6 | 2021 | Joel R. Jung Chief Financial Officer | 319.4K | 141.9K | 126.7K | 464.4K | — | 351.00 | 1.05M | 56.15% | ↗ |
| 7 | 2021 | Dominique J. Filloux Chief Operating Officer | 319.4K | 141.9K | 126.7K | 464.4K | — | 351.00 | 1.05M | 56.15% | ↗ |
| 8 | 2020 | David M. Clapper President and Chief Executive Officer | 440.0K | 250.4K | — | 128.6K | — | — | 818.9K | 15.70% | ↗ |
| 9 | 2020 | Dominique J. Filloux Chief Operating Officer | 286.0K | 66.0K | — | 25.8K | — | — | 377.8K | 6.82% | ↗ |
| 10 | 2020 | Joel R. Jung Chief Financial Officer | 127.3K | 41.6K | — | 51.5K | — | 146.00 | 220.6K | 23.34% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Evgueni V. Skalnyi | Chief Medical Officer | 365.3K | — |
| Brent Palmisano | Chief Commercial Officer | — | male |
| Darin Hammers | Chief Executive Officer | — | male |
| Greg Simbro | Vice President of Finance | — | male |
| Joanne Long | Vice President of Corporate Controller | — | female |
| Wendy Bowman | Vice President of Human Resources | — | female |
ESG Rating
ESG Score History MEDICAL - HEALTHCARE INFORMATION SERVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UTRS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
